亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Uterine serous carcinoma: key advances and novel treatment approaches

医学 浆液性癌 肿瘤科 内科学 浆液性液体 曲妥珠单抗 靶向治疗 子宫内膜癌 三苯氧胺 卵巢癌 癌症 乳腺癌
作者
J. Stuart Ferriss,Britt Erickson,Ie‐Ming Shih,Amanda N. Fader
出处
期刊:International Journal of Gynecological Cancer [BMJ]
卷期号:31 (8): 1165-1174 被引量:58
标识
DOI:10.1136/ijgc-2021-002753
摘要

The incidence and mortality rates from endometrial cancer continue to increase worldwide, while rates in most other cancers have either plateaued or declined considerably. Uterine serous carcinoma represents a fraction of all endometrial malignancies each year, yet this histology is responsible for nearly 40% of all endometrial cancer-related deaths. These deaths disproportionately affect black women, who have higher rates of advanced disease at diagnosis. Molecular genetic analyses reveal major alterations including TP53 mutation, PIK3CA mutation/amplification, ERBB2 amplification, CCNE1 amplification, FBXW7 mutation/deletion, PPP2R1A mutation, and somatic mutations involving homologous recombination genes. Clinical risk factors for uterine serous carcinoma include advancing age, a history of breast cancer, tamoxifen usage, and the hereditary breast-ovarian cancer syndrome. Surgery remains the cornerstone of treatment. Recent advances in our understanding of uterine serous carcinoma molecular drivers have led to development of targeted therapeutics that promise improved outcomes for patients. Overexpression or amplification of HER2 in uterine serous carcinoma carries a poor prognosis; yet this actionable target has led to the incorporation of several anti-HER2 therapies, including trastuzumab which, when added to conventional chemotherapy, is associated with improved survival for women with advanced and recurrent HER2-positive disease. The combination of pembrolizumab and lenvatinib is also a promising targeted treatment strategy for women with uterine serous carcinoma, with a recent phase II study suggesting a 50% response rate in women with recurrent disease. Several trials examining additional targeted agents are ongoing. Despite years of stalled progress, meaningful, tailored treatment options are emerging for patients with this uncommon and biologically aggressive endometrial cancer subtype.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
3秒前
18秒前
18秒前
韩帅发布了新的文献求助10
21秒前
Owen应助韩帅采纳,获得10
24秒前
孟筱完成签到,获得积分10
38秒前
HYQ完成签到 ,获得积分10
54秒前
1分钟前
1分钟前
米老鼠de完成签到,获得积分10
1分钟前
调研昵称发布了新的文献求助20
1分钟前
充电宝应助科研通管家采纳,获得10
2分钟前
科研通AI2S应助科研通管家采纳,获得10
2分钟前
2分钟前
2分钟前
Wei发布了新的文献求助10
2分钟前
puzhongjiMiQ发布了新的文献求助10
2分钟前
2分钟前
金刚经应助puzhongjiMiQ采纳,获得10
3分钟前
万能图书馆应助puzhongjiMiQ采纳,获得10
3分钟前
大模型应助puzhongjiMiQ采纳,获得10
3分钟前
qu蛐应助puzhongjiMiQ采纳,获得10
3分钟前
香蕉觅云应助puzhongjiMiQ采纳,获得10
3分钟前
3分钟前
自信号厂完成签到 ,获得积分10
3分钟前
3分钟前
4分钟前
4分钟前
4分钟前
5分钟前
子车傲之完成签到,获得积分10
5分钟前
星辰大海应助科研通管家采纳,获得10
5分钟前
小泉完成签到 ,获得积分10
5分钟前
6分钟前
氢原子完成签到,获得积分10
6分钟前
6分钟前
完美世界应助着急的一刀采纳,获得10
6分钟前
草木完成签到,获得积分10
6分钟前
zhang发布了新的文献求助10
7分钟前
充电宝应助czb采纳,获得10
7分钟前
高分求助中
Rock-Forming Minerals, Volume 3C, Sheet Silicates: Clay Minerals 2000
The late Devonian Standard Conodont Zonation 2000
Nickel superalloy market size, share, growth, trends, and forecast 2023-2030 2000
The Lali Section: An Excellent Reference Section for Upper - Devonian in South China 1500
Very-high-order BVD Schemes Using β-variable THINC Method 930
The Vladimirov Diaries [by Peter Vladimirov] 600
Development of general formulas for bolted flanges, by E.O. Waters [and others] 600
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3265472
求助须知:如何正确求助?哪些是违规求助? 2905543
关于积分的说明 8334005
捐赠科研通 2575810
什么是DOI,文献DOI怎么找? 1400135
科研通“疑难数据库(出版商)”最低求助积分说明 654702
邀请新用户注册赠送积分活动 633532